Hydrochloric Acid

Hydrochloric Acid

SCHEMBL234912

CO[Si](CCCN=C(N)S)(OC)OC.Cl

nearest known ligand 0.31

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DDAH1 O94760 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL485666 0.98 DDAH1 (0.32) DDAH1LMNA
Hydrochloric Acid SCHEMBL17396301 0.84 MEN1 (0.43)
SCHEMBL11021695 0.82 MEN1 (0.45)
SCHEMBL2501558 0.75 LMNA (0.34) LMNA
SCHEMBL2858567 0.72 LMNA (0.36) LMNA
SCHEMBL31515411 0.72 DDAH1 (0.55) DDAH1
SCHEMBL3841918 0.71 LMNA (0.35) LMNA
SCHEMBL1048862 0.71 LMNA (0.32) LMNA
SCHEMBL28605206 0.71 LMNA (0.32) LMNA
SCHEMBL3841917 0.71 LMNA (0.35) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838173-B1 METHOD OF PREVENTING OR REDUCING OFF-FLAVOR IN A BEVERAGE USING SILANE-TREATED SILICA FILTER MEDIA DOW CORNING (US) 2013-10-16 EP claimed
US-8263153-B2 Method of preventing or reducing haze in a beverage using silane-treated silica filter media DOW CORNING CORPORATION (US) 2012-09-11 US claimed
US-7989010-B2 Method of reducing off-flavor in a beverage using silane-treated silica filter media DOW CORNING CORPORATION (US) 2011-08-02 US claimed
US-7850012-B2 Silane-treated silica filter media DOW CORNING CORPORATION (US) 2010-12-14 US claimed
US-20090232950-A1 METHOD OF PREVENTING OR REDUCING OFF-FLAVOR IN A BEVERAGE USING SILANE-TREATED SILICA FILTER MEDIA DOW CORNING CORPORATION 2009-09-17 US claimed
US-20090214701-A1 Method of preventing or reducing haze in a beverage using silane-treated silica filter media DOW CORNING CORPORATION 2009-08-27 US claimed
US-20080185333-A1 SILANE-TREATED SILICA FILTER MEDIA DOW CORNING CORPORATION 2008-08-07 US claimed
US-7374684-B2 Method of separating components in a sample using silane-treated silica filter media DOW CORNING CORPORATION (US) 2008-05-20 US claimed
US-20070267349-A1 METHOD OF SEPARATING COMPONENTS IN A SAMPLE USING SILANE-TREATED SILICA FILTER MEDIA DOW CORNING CORPORATION 2007-11-22 US claimed
EP-1838173-A2 METHOD OF PREVENTING OR REDUCING OFF-FLAVOR IN A BEVERAGE USING SILANE-TREATED SILICA FILTER MEDIA DOW CORNING CORPORATION (US) 2007-10-03 EP claimed
WO-2005115580-A2 METHOD OF SEPARATING COMPONENTS IN A SAMPLE USING SILANE-TREATED SILICA FILTER MEDIA GENENCOR INTERNATIONAL, INC. (US) 2005-12-08 WO claimed
US-20050029195-A1 Method of separating components in a sample using silane-treated silica filter media DOW CORNING CORPORATION 2005-02-10 US claimed
WO-2005002530-A1 A METHOD OF PRODUCING A SILANIZED COMPOSITE FILLER AND A METHOD OF PRODUCING A COMPOSITE MATERIAL NANON A/S (DK) 2005-01-13 WO claimed
EP-0989933-B1 DIRECT WRITE LITHOGRAPHIC PRINTING PLATES KODAK POLYCHROME GRAPHICS LLC (US) 2002-07-03 EP claimed
US-20020041856-A1 Use of an organometallic compound to protect and/or strengthen a keratin material, and treatment process JEANNE-ROSE VALERIE (FR) 2002-04-11 US claimed
EP-0637902-B1 Metallic foil with adhesion promoting layer GOULD ELECTRONICS INC (US) 1999-03-31 EP claimed
EP-0637902-A1 Metallic foil with adhesion promoting layer GOULD ELECTRONICS INC. (US) 1995-02-08 EP claimed
EP-0586384-A1 ORAL AND PERSONAL HYGIENE ARTICLES CONTAINING ACTIVE AGENTS BONDED TO THE SURFACE THEREOF WARNER-LAMBERT COMPANY (US) 1994-03-16 EP claimed
WO-1992015198-A1 ORAL AND PERSONAL HYGIENE ARTICLES CONTAINING ACTIVE AGENTS BONDED TO THE SURFACE THEREOF WARNER-LAMBERT COMPANY (US) 1992-09-17 WO claimed
US-5082581-A Aqueous magnetic fluid composition and process for producing thereof NIPPON SEIKO KABUSHIKI KAISHA (JP) 1992-01-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020041856-A1 Use of an organometallic compound to protect and/or strengthen a keratin material, and treatment process KRT18, VIM, CDH1 DDAH1 2968/4885LMNA 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.